CoChat

Hepatocyte Growth Factor Enhances Engraftment and Function of Nonhuman Primate Islets

Open access
Fiaschi-Taesch, Nathalie M., Berman, Dora M., Sicari, Brian M., Takane, Karen K., Garcia-Ocaña, Adolfo, Ricordi, Camillo, Kenyon, Norma S., Stewart, Andrew F. · 2008 · Diabetes

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

OBJECTIVE—Adenoviral delivery of hepatocyte growth factor (HGF) to rodent islets improves islet graft survival and function, markedly reducing the number of islets required to achieve glucose control. Here, we asked whether these prior observations in rodent models extend to nonhuman primate (NHP) islets. RESEARCH DESIGN AND METHODS—NHP islets were transduced with murine (Ad.mHGF) or human (Ad.hHGF) adenoviral HGF (Ad.HGF) at low multiplicity of infection and studied in vitro. To study the function of Ad.HGF-transduced NHP islets in vivo, a renal subcapsular marginal mass islet transplant model was developed in streptozotocin-induced diabetic NOD-SCID mice. RESULTS—Baseline glucose values were 454.7 ± 11.3 mg/dl (n = 7). Transplant of 500 NHP islet equivalents (IE) had only a marginal effect on blood glucose (369.1 ± 9.7 mg/dl, n = 5). In striking contrast, 500 NHP IE transduced with Ad.mHGF promptly and continuously corrected blood glucose (142.0 ± 6.2 mg/dl, n = 7) for the 6-week duration of the experiment. Unilateral nephrectomy resulted in an immediate return of glucose to baseline diabetic levels. Interestingly, adenoviral DNA, as well as mouse HGF (mHGF) mRNA derived from the adenovirus, were present for 42 days posttransplantation. Surprisingly, transplant of 500 IE with Ad.hHGF, as compared with Ad.mHGF, resulted in only marginal correction of blood glucose, suggesting that human HGF is less efficient than mHGF in this system. CONCLUSIONS—These studies demonstrate that mHGF markedly improves islet transplant outcomes in the highest preclinical species examined to date. HGF has promise as an agent that can improve islet mass and function in transplant models and likely in other models of types 1 and 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db07-1085

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. β-Cell composition in NHP islets. A–D: Insulin immunofluorescence (green) and Hoechst (blue) staining in NHP islets. E and F: Insulin immunofluorescence (green) and Hoechst (blue) staining in human islets. Note that the large majority of NHP islets contain ∼70% β-cells, which compares very favorably with isolated human islets (9,17,18,20). (Please see http://dx.doi.org/10.2337/db08-1085 for a high-quality representation of this figure.)
FIG. 1. β-Cell composition in NHP islets. A–D: Insulin immunofluorescence (green) and Hoechst (blue) staining in NHP islets. E and F: Insulin immunofluorescence (green) and Hoechst (blue) staining in human islets. Note that the large majority of NHP islets contain ∼70% β-cells, which compares very favorably with isolated human islets (9,17,18,20). (Please see http://dx.doi.org/10.2337/db08-1085 for a high-quality representation of this figure.)CC BY-NC-ND · PubMed Central
FIG. 2. Glucose-stimulated insulin secretion and HGF expression in nontransduced and transduced NHP islets. A: NHP islets were exposed to 250–500 MOI for 1 h. At 24 h after transduction, groups of 15 IE of similar size were incubated with 5 or 22 mmol/l glucose for 30 min, and insulin secreted into the media was measured by radioimmunoassay. Results are the means ± SE of 5–13 experiments performed in triplicate. The data are presented as the percentage above the insulin secreted by uninfected islets (100%). B and C: HGF expression as assessed by RT-PCR (B) and Western blot (C) analysis of RNA extracts and protein extracts obtained from nontransduced NHP islets and islets transduced with 250 MOI of Ad.LacZ, Ad.GFP, Ad.mHGF, or Ad.hHGF. At 24 h after transduction, islets were harvested and mRNA and protein were extracted. For the RT-PCR, primers were specifically designed to amplify either mHGF or hHGF cDNA, as appropriate. HGF was detected using an antibody recognizing both mHGF and hHGF. Actin was used as an internal control for loading. Note that both Ad.mHGF and Ad.hHGF were able to transduce NHP islets equally as assessed by RT-PCR and Western blot.
FIG. 2. Glucose-stimulated insulin secretion and HGF expression in nontransduced and transduced NHP islets. A: NHP islets were exposed to 250–500 MOI for 1 h. At 24 h after transduction, groups of 15 IE of similar size were incubated with 5 or 22 mmol/l glucose for 30 min, and insulin secreted into the media was measured by radioimmunoassay. Results are the means ± SE of 5–13 experiments performed in triplicate. The data are presented as the percentage above the insulin secreted by uninfected islets (100%). B and C: HGF expression as assessed by RT-PCR (B) and Western blot (C) analysis of RNA extracts and protein extracts obtained from nontransduced NHP islets and islets transduced with 250 MOI of Ad.LacZ, Ad.GFP, Ad.mHGF, or Ad.hHGF. At 24 h after transduction, islets were harvested and mRNA and protein were extracted. For the RT-PCR, primers were specifically designed to amplify either mHGF or hHGF cDNA, as appropriate. HGF was detected using an antibody recognizing both mHGF and hHGF. Actin was used as an internal control for loading. Note that both Ad.mHGF and Ad.hHGF were able to transduce NHP islets equally as assessed by RT-PCR and Western blot.CC BY-NC-ND · PubMed Central
FIG. 3. Blood glucose levels in STZ-induced diabetic NOD-SCID mice transplanted with uninfected or infected NHP islets. A: Defining the NHP marginal mass. At 24 h after mock transduction, 500, 1,000, or 2,000 IE of NHP islets were transplanted under the kidney capsule of STZ-induced NOD-SCID mice. Identical surgery was performed on the sham-operated animals, except that they received saline instead of islets. Results are the means ± SE of four to seven animals per condition. At day 42, unilateral nephrectomy (UNX) was performed in mice transplanted with either 1,000 or 2,000 control IE or with 500 Ad.mHGF IE, and the blood glucose returned immediately to pretransplant diabetic levels. B: Effect of Ad.HGF on NHP islet transplant outcome. At 24 h after transduction, 500 Ad.LacZ, Ad.mHGF, or Ad.hHGF IE were transplanted under the kidney capsule of STZ-induced NOD-SCID mice. Results are the means ± SE of five to seven animals per condition.
FIG. 3. Blood glucose levels in STZ-induced diabetic NOD-SCID mice transplanted with uninfected or infected NHP islets. A: Defining the NHP marginal mass. At 24 h after mock transduction, 500, 1,000, or 2,000 IE of NHP islets were transplanted under the kidney capsule of STZ-induced NOD-SCID mice. Identical surgery was performed on the sham-operated animals, except that they received saline instead of islets. Results are the means ± SE of four to seven animals per condition. At day 42, unilateral nephrectomy (UNX) was performed in mice transplanted with either 1,000 or 2,000 control IE or with 500 Ad.mHGF IE, and the blood glucose returned immediately to pretransplant diabetic levels. B: Effect of Ad.HGF on NHP islet transplant outcome. At 24 h after transduction, 500 Ad.LacZ, Ad.mHGF, or Ad.hHGF IE were transplanted under the kidney capsule of STZ-induced NOD-SCID mice. Results are the means ± SE of five to seven animals per condition.CC BY-NC-ND · PubMed Central
FIG. 4. Islet graft histology 42 days after transplantation. Representative photomicrographs of kidney sections containing the grafts at day 42 after transplant and staining for insulin. (Please see http://dx.doi.org/10.2337/db08-1085 for a high-quality representation of this figure.)
FIG. 4. Islet graft histology 42 days after transplantation. Representative photomicrographs of kidney sections containing the grafts at day 42 after transplant and staining for insulin. (Please see http://dx.doi.org/10.2337/db08-1085 for a high-quality representation of this figure.)CC BY-NC-ND · PubMed Central
FIG. 5. Adenoviral persistence in islet grafts after transplantation. A: Viral constructs and primers. The primers were designed to specifically amplify only mHGF DNA derived from the adenovirus. Primers used were 5′-GCC ATG CCA AAT CGT CCT GG-3′ and reverse 3′-GTA GTT TGT CCA ATT ATG TCA CAC CAC-5′ for Ad.mHGF and 5′-CAT TCC AAA TAT GAG ATG CAT TG-3′ and reverse 5′-TAA AAA AGT ATT AAG GCG AAG ATT A-3′ for NHP actin. B: Persistence of viral DNA in vitro. NHP islets transduced with Ad.mHGF at 250 MOI were harvested 24 h after transduction. INS1 cells were transduced with Ad.mHGF at 1,000 MOI for 1 h and were used as a positive control. Note that NHP actin is only present in NHP islets, but not in INS1 cells. C: Assessment of viral DNA in vivo. Kidneys bearing the NHP islet graft transduced with Ad.mHGF, and contralateral kidneys containing no islet graft were harvested 24 h and 7, 14, 28, and 42 days after transplant. DNA and RNA were extracted. INS1 cells infected with Ad.mHGF were used as a positive control. Note that the adenoviral DNA was still abundant 42 days after transplant in kidneys bearing the graft. The presence of the graft was confirmed by the presence of NHP actin. Kidneys with no islet grafts were negative for mouse HGF and NHP actin but were positive for glyceraldehyde-3-phosphate dehydrogenase (GAPDH). D: Assessment of viral mRNA in vivo. The presence of viral mouse HGF and NHP actin mRNAs was confirmed in kidneys bearing the NHP grafts, whereas contralateral kidneys were negative. INS1 cells transduced with Ad.mHGF were used as positive controls. E: Control PCR from mRNA samples used in D with no reverse transcriptase (RT). To confirm that no genomic DNA contaminated the samples used in D, PCR was performed on the same samples used in D but with no reverse transcriptase. INS1 cells transduced with Ad.mHGF were used as a positive control. RT was performed before the PCR. Note that only the INS1 cells were positive, confirming that samples used in D were free of contaminating DNA.
FIG. 5. Adenoviral persistence in islet grafts after transplantation. A: Viral constructs and primers. The primers were designed to specifically amplify only mHGF DNA derived from the adenovirus. Primers used were 5′-GCC ATG CCA AAT CGT CCT GG-3′ and reverse 3′-GTA GTT TGT CCA ATT ATG TCA CAC CAC-5′ for Ad.mHGF and 5′-CAT TCC AAA TAT GAG ATG CAT TG-3′ and reverse 5′-TAA AAA AGT ATT AAG GCG AAG ATT A-3′ for NHP actin. B: Persistence of viral DNA in vitro. NHP islets transduced with Ad.mHGF at 250 MOI were harvested 24 h after transduction. INS1 cells were transduced with Ad.mHGF at 1,000 MOI for 1 h and were used as a positive control. Note that NHP actin is only present in NHP islets, but not in INS1 cells. C: Assessment of viral DNA in vivo. Kidneys bearing the NHP islet graft transduced with Ad.mHGF, and contralateral kidneys containing no islet graft were harvested 24 h and 7, 14, 28, and 42 days after transplant. DNA and RNA were extracted. INS1 cells infected with Ad.mHGF were used as a positive control. Note that the adenoviral DNA was still abundant 42 days after transplant in kidneys bearing the graft. The presence of the graft was confirmed by the presence of NHP actin. Kidneys with no islet grafts were negative for mouse HGF and NHP actin but were positive for glyceraldehyde-3-phosphate dehydrogenase (GAPDH). D: Assessment of viral mRNA in vivo. The presence of viral mouse HGF and NHP actin mRNAs was confirmed in kidneys bearing the NHP grafts, whereas contralateral kidneys were negative. INS1 cells transduced with Ad.mHGF were used as positive controls. E: Control PCR from mRNA samples used in D with no reverse transcriptase (RT). To confirm that no genomic DNA contaminated the samples used in D, PCR was performed on the same samples used in D but with no reverse transcriptase. INS1 cells transduced with Ad.mHGF were used as a positive control. RT was performed before the PCR. Note that only the INS1 cells were positive, confirming that samples used in D were free of contaminating DNA.CC BY-NC-ND · PubMed Central
FIG. 6. β-Cell proliferation and insulin content in islet grafts 5 days after transplant. A: Representative photomicrographs of renal subcapsular grafts obtained at days 3, 5, and 10 after transplant in control islet grafts or islet grafts transduced with Ad.mHGF showing BrdU (red) and insulin (green) staining. Arrowheads indicate BrdU-positive cells. B: Quantification of BrdU proliferation in the islet grafts. The numbers in green indicate the numbers of β-cells counted, and those in red, the number of BrdU-positive cells. There were no statistically significant differences between Ad.mHGF and control islet grafts. Results are the means ± SE. Three different grafts per condition were examined. (Please see http://dx.doi.org/10.2337/db08-1085 for a high-quality representation of this figure.)
FIG. 6. β-Cell proliferation and insulin content in islet grafts 5 days after transplant. A: Representative photomicrographs of renal subcapsular grafts obtained at days 3, 5, and 10 after transplant in control islet grafts or islet grafts transduced with Ad.mHGF showing BrdU (red) and insulin (green) staining. Arrowheads indicate BrdU-positive cells. B: Quantification of BrdU proliferation in the islet grafts. The numbers in green indicate the numbers of β-cells counted, and those in red, the number of BrdU-positive cells. There were no statistically significant differences between Ad.mHGF and control islet grafts. Results are the means ± SE. Three different grafts per condition were examined. (Please see http://dx.doi.org/10.2337/db08-1085 for a high-quality representation of this figure.)CC BY-NC-ND · PubMed Central
FIG. 7. Cell death rates in Ad.mHGF-treated islets in vitro and in vivo. A: Representative photomicrographs of TUNEL staining in vitro in isolated control islets or those transduced with Ad.mHGF 48 h previously. Insulin is shown in red and TUNEL staining in green. Arrows indicate examples of TUNEL-positive β-cells. B: Quantification of TUNEL-positive, insulin-positive cells. The numbers indicate the numbers of cells counted as in Fig. 6. Bars indicate SE C: Examples of TUNEL-positive β-cells in islet grafts 3 days after transduction and transplantation. Arrows indicate examples of TUNEL-positive β-cells. D: Quantitation of TUNEL-positive/insulin-positive cells in islet grafts in vivo. These observations demonstrate that Ad.mHGF treatment reduces cell death in vitro and in vivo. hHGF, human HGF; mHGF, mouse HGF. (Please see http://dx.doi.org/10.2337/db08-1085 for a high-quality representation of this figure.)
FIG. 7. Cell death rates in Ad.mHGF-treated islets in vitro and in vivo. A: Representative photomicrographs of TUNEL staining in vitro in isolated control islets or those transduced with Ad.mHGF 48 h previously. Insulin is shown in red and TUNEL staining in green. Arrows indicate examples of TUNEL-positive β-cells. B: Quantification of TUNEL-positive, insulin-positive cells. The numbers indicate the numbers of cells counted as in Fig. 6. Bars indicate SE C: Examples of TUNEL-positive β-cells in islet grafts 3 days after transduction and transplantation. Arrows indicate examples of TUNEL-positive β-cells. D: Quantitation of TUNEL-positive/insulin-positive cells in islet grafts in vivo. These observations demonstrate that Ad.mHGF treatment reduces cell death in vitro and in vivo. hHGF, human HGF; mHGF, mouse HGF. (Please see http://dx.doi.org/10.2337/db08-1085 for a high-quality representation of this figure.)CC BY-NC-ND · PubMed Central
FIG. 8. Differential effects mouse HGF and human HGF on p42/44 mitogen-activated protein kinase activity in primary murine arterial smooth muscle cells. A: Effects of human HGF (hHGF) and mouse HGF (mHGF) peptides at 25 ng/ml on total ERK and phospho-ERK in primary cultures of murine aortic smooth muscle cells. Note that human HGF fails to activate mitogen-activated protein kinase in mouse arterial smooth muscle cells, whereas mouse HGF readily activates mitogen-activated protein kinase. To insure that the human HGF was active, it was also assayed in rat INS-1 cells: the panel on the far right demonstrates that the identical human HGF preparation that failed to activate mitogen-activated protein kinase in the vascular smooth muscle cells (VSMC) was robustly active in INS-1 cells. B: Densitometric quantification of three experiments as outlined in A. These studies demonstrate that whereas the human HGF peptide is active, it is unable to activate mitogen-activated protein kinase in murine arterial smooth muscle cells, in contrast to mouse HGF, which is active in these same cells. NTx, no treatment.
FIG. 8. Differential effects mouse HGF and human HGF on p42/44 mitogen-activated protein kinase activity in primary murine arterial smooth muscle cells. A: Effects of human HGF (hHGF) and mouse HGF (mHGF) peptides at 25 ng/ml on total ERK and phospho-ERK in primary cultures of murine aortic smooth muscle cells. Note that human HGF fails to activate mitogen-activated protein kinase in mouse arterial smooth muscle cells, whereas mouse HGF readily activates mitogen-activated protein kinase. To insure that the human HGF was active, it was also assayed in rat INS-1 cells: the panel on the far right demonstrates that the identical human HGF preparation that failed to activate mitogen-activated protein kinase in the vascular smooth muscle cells (VSMC) was robustly active in INS-1 cells. B: Densitometric quantification of three experiments as outlined in A. These studies demonstrate that whereas the human HGF peptide is active, it is unable to activate mitogen-activated protein kinase in murine arterial smooth muscle cells, in contrast to mouse HGF, which is active in these same cells. NTx, no treatment.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

Metadata

Authors
Fiaschi-Taesch, N. M., Berman, D. M., Sicari, B. M., Takane, K. K., Garcia-Ocaña, A., Ricordi, C., Kenyon, N. S., & Stewart, A. F.
Affiliations
  • Division of Endocrinology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
  • University of Miami (US)
  • University of Pittsburgh (US)
Venue
Diabetes
Published
2008-10-01
Volume
57
Issue
10
Pages
2745-2754
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2153745698
Cited by
59
References
25
Citations by year
2025: 1 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 3 · 2020: 3 · 2019: 5 · 2018: 4 · 2017: 2 · 2016: 3 · 2015: 4 · 2014: 3 · 2013: 1 · 2012: 6
FWCI
7.03
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK R-33 066127, DK-R-01-067351, R33DK066127)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
hepatocyte growth factor, islet transplantation, adenoviral gene transfer, islet engraftment, islet function, type 1 diabetes, type 2 diabetes, streptozotocin-induced diabetes, NOD/SCID mice
MeSH terms
Adenoviridae, Animals, Genetic Vectors, Graft Survival, Immunohistochemistry, Insulin, Islets of Langerhans, Macaca fascicularis, Islets of Langerhans Transplantation, Mice, SCID, Mice, Inbred NOD, Hepatocyte Growth Factor, Mitogen-Activated Protein Kinases, Cell Proliferation, Insulin-Secreting Cells, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.